1. ALLA AKTIER
  2. NYHETER
  3. SENZAGEN

SenzaGen

Nyheter SenzaGen Nyheter alla bolag

SenzaGen’s 2023 Half-Year Report: Continued growth, improved gross margin and lower loss

MAR

Message from the CEO
“We are continuing to attract new customers and scale up our business with a substantially improved gross margin and a lower loss to show for it. Sales were up 18% from the strong comparative period last year, and we have seen a significant increase in interest during the period that has not yet been reflected in our sales figures. As a result, we expect an even higher return on our investments in the second half of the year. With the strong growth of our customer portfolio, high demand from pharmaceuticals companies, successful cross selling within the Group, and increased profitability, I have a very positive view of the second half of the year and the future of non-animal testing based on our unique methods.”

Peter Nählstedt, President and CEO

Half year 1 January–30 June

  • Net sales totaled SEK 23.6 (19.9) million.
  • EBITDA amounted to SEK -6.8 (-9.1) million.
  • Earnings per share were SEK -0.51 (-0.56).
  • Cash and cash equivalents at 30 June amounted to SEK 25.1 (49.0) million.

Significant events during the first half year

  • SenzaGen won an order for GARD®skin worth about SEK 1 million from a new chemicals customer.

Significant events after the end of the period

  • SenzaGen strengthened its market presence with expanded distribution channels in India and France.

Contacts

Peter Nählstedt, President and CEO, SenzaGen AB
Email: peter.nahlstedt@senzagen.com | Mobile: +46 700 23 44 31

Tina Dackemark Lawesson, VP Marketing & Communications
Email: tina.lawesson@senzagen.com | Mobile: +46 708 20 29 44

About us

SenzaGen aims to be a leader in in vitro science and testing, driving the transition from animal testing to methods better suited to reflect human biology. The Company provides high-performance, non-animal test methods and innovation and consulting services based on state-of-the-art technology. Non-animal methods are more effective, more accurate and less expensive than traditional animal-based methods while also helping to reduce the number of laboratory animals. The Company has a growth strategy centered around continued commercialization of its proprietary GARD® and VitroScreen ORA® test platforms, expansion of its test portfolio and evaluation of acquisition opportunities of profitable and growing companies with complementary offerings. SenzaGen has its headquarters and GLP-certified laboratory in Lund, Sweden and subsidiaries in the US and Italy. For more information, please visit: www.senzagen.com.

SenzaGen is listed on Nasdaq Stockholm First North (ticker: SENZA). FNCA Sweden AB is the company’s Certified Adviser. 

This information is information that SenzaGen is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2023-08-24 08:30 CEST.

Attachments

SenzaGen AB (publ) Half Year Report 2023

Datum 2023-08-24, kl 08:30
Källa MFN
Bifogade filer
SenzaGen AB (publ) Half Year Report 2023
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 100 000 sidvisningar och 10 000 unika besökare per månad. Vår discord har över 5000 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!